Bristol-Myers Squibb's Capoten (captopril)
Approved Jan. 28 for use in patients with Type I insulin- dependent diabetes mellitus and retinopathy. FDA's Cardiovascular & Renal Drugs Advisory Committee recommended approval for the angiotensin-converting enzyme inhibitor following an Oct. 28 FDA Advisory Committee meeting ("The Pink Sheet" Nov. 1, 1993, T&G-7). Capoten received a positive endorsement from a BMS/National Institute of Diabetes & Digestive Kidney Diseases study published in the New England Journal of Medicine on Nov. 11 and more recently from a European study published in the Jan. 26 issue of Journal of the American Medical Association
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth